Funder: Breakthrough T1D
Due Dates: October 29, 2025 (LOI) | January 13, 2026 (Full proposal)
Funding Amounts: Up to $3,000,000 total for up to 3 years; budget must match project scope; 10% indirect costs allowed for non-profit applicants.
Summary: Supports clinical trials to advance therapies targeting cardiovascular disease in people with type 1 diabetes, aiming to improve clinical outcomes in this high-risk population.
Key Information: LOI is required before full proposal; both academic and industry applicants are eligible.